Company intelligence / Profile preview

Stone

Cambridge, Massachusetts, United Statesbrevardschools.org ↗

Ownership: Private
Development stage: Commercial

Overview

River Stone Biotech has developed a hybrid platform combining synthetic biology with traditional chemistry to manufacture specialty alkaloid APIs such as buprenorphine, naloxone, and naltrexone. These products are approved by global regulatory authorities for treating opioid use disorder, alcohol use disorder, pain management, and opioid overdose. Their process reduces complexity and cost compared to traditional methods.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule (specifically, specialty alkaloid APIs such as buprenorphine, naloxone, naltrexone)
Industry: Biotech

Beyond the preview

Go deeper on Stone.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stone.

Explore the full profile